Sugi Predict

Sugi Predict / Targets / PDE6H

PDE6H

Retinal cone rhodopsin-sensitive cGMP 3',5'-c · Q13956 · PDE6H on Sugi Atlas →

11,695 patent compounds predicted against PDE6H, 9,637 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1327741 SCHEMBL1327741 0.79 6/20
SCHEMBL1327318 SCHEMBL1327318 0.81 5/20
SCHEMBL1327321 SCHEMBL1327321 0.81 5/20
SCHEMBL1327324 SCHEMBL1327324 0.81 5/20
SCHEMBL972494 SCHEMBL972494 0.72 5/20
SCHEMBL972096 SCHEMBL972096 0.60 5/20
SCHEMBL2792231 SCHEMBL2792231 0.54 5/20
SCHEMBL969605 SCHEMBL969605 0.77 4/20
SCHEMBL2791914 SCHEMBL2791914 0.63 4/20
SCHEMBL2485688 SCHEMBL2485688 0.58 4/20
SCHEMBL969760 SCHEMBL969760 0.51 4/20
SCHEMBL1696249 SCHEMBL1696249 0.51 4/20
SCHEMBL2576880 SCHEMBL2576880 1.00 3/20
SCHEMBL2840425 SCHEMBL2840425 0.75 3/20
SCHEMBL2568447 SCHEMBL2568447 0.74 3/20
SCHEMBL968670 SCHEMBL968670 0.73 3/20
SCHEMBL972290 SCHEMBL972290 0.73 3/20
SCHEMBL971800 SCHEMBL971800 0.72 3/20
SCHEMBL867299 SCHEMBL867299 0.72 3/20
SCHEMBL1326458 SCHEMBL1326458 0.72 3/20

Clinical trials — most relevant to PDE6H by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Oral N-acetylcysteine for Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
PDE6A Gene Therapy for Retinitis Pigmentosa PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Promising ROd-cone DYstrophy Gene therapY PHASE1/PHASE2ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder PHASE2UNKNOWN
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study PHASE2UNKNOWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
A Study in Subjects With Retinitis Pigmentosa PHASE2COMPLETED
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye PHASE1COMPLETED
Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults PHASE1COMPLETED
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 PHASE1COMPLETED
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa PHASE1COMPLETED
A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women PHASE1COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Prospective Natural History Study of Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Retrospective Natural History Study of Retinitis Pigmentosa nanUNKNOWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Is Pentoxifylline Able to Improve Olfactory Sensitivity? nanCOMPLETED
Endurance Performance at Altitude nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a PDE6H binder may also engage these)

ProteinNameSimilarity
O55175 — 1.000 O55175 →
P61250 — 1.000 P61250 →
P22571 — 1.000 P22571 →
Q9EQQ8 — 0.998 Q9EQQ8 →
P28974 — 0.996 P28974 →
A1DL98 — 0.996 A1DL98 →
P61249 — 0.996 P61249 →
P61248 — 0.996 P61248 →
A3EXD7 — 0.995 A3EXD7 →
BTF3 Transcription factor BTF3 0.995 landscape →
Q64152 — 0.994 Q64152 →
P04972 — 0.994 P04972 →
P12648 — 0.994 P12648 →
A4RC23 — 0.994 A4RC23 →
A6S6B0 — 0.993 A6S6B0 →
Q04558 — 0.993 Q04558 →
Q7T2A3 — 0.993 Q7T2A3 →
Q82616 — 0.993 Q82616 →
Q96GT9 — 0.993 Q96GT9 →
Q9Y7I1 — 0.993 Q9Y7I1 →
P03045 — 0.993 P03045 →
PDE6G Rod cGMP 3',5'-cyclic phosphodiesterase subun 0.992 landscape →
Q14EA6 — 0.992 Q14EA6 →
Q9WCD0 — 0.992 Q9WCD0 →
Q06428 — 0.992 Q06428 →
P84395 — 0.992 P84395 →
Q2U6N1 — 0.992 Q2U6N1 →
Q9D992 — 0.992 Q9D992 →
Q4I283 — 0.992 Q4I283 →
Q9PY96 — 0.992 Q9PY96 →